Pfizer 2016 Global Healthcare Conference Presentation

Pfizer's R&D leadership presents on the company's strong track record in drug approvals and robust clinical pipeline. The presentation highlights over 30 Phase 3 starts and 15 key approvals over six years, with approximately 50% of projects focused on biologics, biosimilars, and vaccines.